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Abstract
Pseudomonas aeruginosa is an opportunistic bacterial pathogen and major cause of healthcare-
associated infections. While the organism’s intrinsic and acquired resistance to most antibiotics
hinders treatment of P. aeruginosa infections, the regulatory networks controlling its virulence
provide novel targets for drug development. CyaB, a key regulator of P. aeruginosa virulence,
belongs to the Class III adenylyl cyclase (AC) family of enzymes that synthesize the second
messenger cyclic adenosine 3′,5′-monophosphate (cAMP). These enzymes consist of a conserved
catalytic domain fused to one or more regulatory domains. We describe here the biochemical and
structural characterization of CyaB and its inhibition by small molecules. We show that CyaB
belongs to the Class IIIb subfamily and, like other subfamily members, its activity is stimulated by
inorganic carbon. CyaB is also regulated by its N-terminal MASE2 domain, which acts as a
membrane anchor. Using a genetic screen, we identified activating mutations in CyaB. By solving
the crystal structure of the CyaB catalytic domain, we rationalized the effects of these mutations
and propose that CyaB employs regulatory mechanisms similar to other Class III ACs. The CyaB
structure further indicates subtle differences compared to other Class III ACs in both the active
and inhibitor binding pocket. Consistent with these differences, we observed a unique inhibition
profile, including identification of a CyaB selective compound. Overall, our results reveal
mechanistic details of the physiological and pharmacological regulation of CyaB and provide the
basis for its exploitation as a therapeutic drug target.
© 2011 Elsevier Ltd. All rights reserved.
*Correspondence should be addressed to: Clemens Steegborn, University of Bayreuth, Dept. of Biochemistry, Universitätsstr. 30,
95447 Bayreuth, Germany; phone: (49)(921)552421; fax: (49)(921)552432; Clemens.Steegborn@uni-bayreuth.de.
ACCESSION NUMBERS: Coordinates and structure factors for the crystalstructure of CyaB have been deposited with the Protein
Data Bank under accession code 3R5G.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Mol Biol. Author manuscript; available in PMC 2013 February 17.
Published in final edited form as:














Class III; adenylyl cyclase; inhibition; activation; regulation mechanism
INTRODUCTION
Pseudomonas aeruginosa is a common cause of nosocomial and community-acquired
pneumonia, and the primary cause of mortality in individuals with cystic fibrosis 1; 2.
Treatment of P. aeruginosa infections is handicapped by the bacterium’s high intrinsic and
acquired antibiotic resistance 3, which has left few effective treatment options 4. The
regulatory networks controlling P. aeruginosa virulence gene expression represent novel
targets for drug development. Multiple P. aeruginosa virulence systems are controlled by
the second messenger cyclic adenosine 3′, 5′-monophosphate (cAMP) via the cAMP-
dependent global transcriptional regulator Vfr 5; 6; 7. cAMP is formed by adenylyl cyclase
(AC), and P. aeruginosa has three such enzymes. ACs can be grouped into six evolutionary
distinct classes 8; 9. P. aeruginosa ExoY belongs to Class II 10, a small group of secreted
bacterial ACs that act as toxins. The two other P. aeruginosa ACs, CyaA and CyaB, belong
to Class I and III, respectively. Class I enzymes are found exclusively in bacteria and are
best known for their role in regulating nutrient utilization 8. As yet, the role of P. aeruginosa
CyaA is unknown. Class III is the largest family, which comprises members in almost all
organisms including all mammalian ACs and guanylyl cyclases (GCs). Class III ACs have
diverse cellular functions, including regulation of virulence mechanisms in several microbial
pathogens. In P. aeruginosa, CyaB activity indeed accounts for the majority of intracellular
cAMP and only CyaB is essential for P. aeruginosa colonization and dissemination in a
mouse model of acute pneumonia 11. CyaB activity appears to be triggered by
environmental signals and we recently showed that CyaB is regulated by the Chp
chemotaxis-like chemosensing system 12; however, the exact environmental trigger and
activation mechanisms remain to be identified.
Class III ACs possess one or more regulatory domains fused to the AC catalytic
domain 13; 14. Two catalytic domains, either from two polypeptides or from a single protein
chain, form a (pseudo)dimeric C1C2 catalytic core. A variety of Class III crystal
structures 15; 16; 17; 18 demonstrate that both monomers contribute conserved catalytic
residues to the two active sites at the dimer interface. Two catalytic Mg2+ ions are co-
ordinated by two Asp residues from C1, and the transition state is stabilised by an Asp-Arg
pair from C29; 19. Nucleotide specificity is primarily determined by a Lys from C1 and an
Asp from C2, which bind to the ATP base 9; 18. CyaB belongs to the Class III subgroup
IIIb 20, where this Asp is exchanged for a Thr. This feature appears to correlate with
sensitivity to inorganic carbon; i.e., the constituents of dissolved carbon dioxide (CO2),
including bicarbonate (HCO3−), carbonic acid, and carbonate (from now on referred to as
CO2/HCO3−). Stimulation by CO2/HCO3− was first reported for the catalytic core of
mammalian soluble adenylyl cyclase (sAC), and subsequently for catalytic domains of other,
microbial “sAC-like” IIIb enzymes 16; 21; 22. Although CO2/HCO3− activation is unique for
“sAC”-like ACs, the molecular mechanisms involved are assumed to share similarities with
regulation by other stimuli, such as G-proteins or pH, and to be based on the relative rotation
of catalytic domains and transitions between open and closed active site
conformations15; 16; 23.
In CyaB, the catalytic domain is fused to an N-terminal MASE2 (membrane associated
sensor 2) domain 24. MASE2 is a predicted transmembrane module found in a limited
number of bacterial Class III ACs and diguanylyl cyclases. MASE2 domains are assumed to
serve as sensors for environmental signals, relaying the signal to the cytosol by regulating
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the activity of the fused catalytic domain. However, the exact roles of MASE2 domains in
general and in CyaB in particular remain to be revealed.
Their role in virulence regulation renders microbial ACs interesting drug targets. In the
fungal pathogen Cryptococcus neoformans, a CO2-sensing AC regulates virulence, and
interfering with this system prevents virulent growth 25; 26. Interestingly, the regulation of
Class IIIb ACs correlates with the sensitivity to established AC inhibitors: Class IIIb
enzymes are sensitive to the synthetic compounds KH7 and BCC2/8, whereas other Class III
ACs show a higher sensitivity to so-called P-site inhibitors, nucleotide derivatives which
block the substrate binding pocket 9; 27; 28; 29. It thus appears that specific inhibition of
microbial ACs can be achieved and insights into the molecular details of the physiological
and pharmacological regulation of such enzymes are an important step toward anti-infective
compounds with novel mechanisms of action.
Here, we describe the biochemical and structural characterization of CyaB from P.
aeruginosa. We determined that the MASE2 domain is required for significant catalytic
activity in vivo and anchors the catalytic domain to the cytoplasmic membrane. We
identified CyaB residues involved in the regulation of AC activity using a random
mutagenesis strategy and gain-of-function screen, and solved the crystal structure of the
CyaB catalytic domain to analyze the location and function of these residues. We further
describe the modulation of CyaB through CO2/HCO3− and known AC inhibitors. Our
results are a first step toward understanding the physiological regulation of CyaB and to
exploit it as a drug target.
RESULTS
The CyaB N-terminal region controls catalytic activity
P. aeruginosa CyaB (UniProt Q9HZ23) regulates virulence factor expression and has been
implicated in coupling this process to environmental signals 12. Importantly, a P. aeruginosa
cyaB mutant is attenuated in a mouse pneumonia model 11. Because these observations
suggest that the enzyme may serve as a drug target, we set out to study its physiological and
pharmacological regulation. We previously showed that the C-terminal AC homology region
of CyaB has catalytic activity in vitro 12; we now explored whether regions outside the
catalytic domain play a role in CyaB activation. We investigated how AC activity is affected
by i) the extreme N-terminal segment, which is basic, proline-rich, and predicted to be
cytoplasmically exposed and ii) the putative MASE2 sensing domain, which contains
multiple transmembrane segments (Figure 1a). We constructed cyaB alleles in which
nucleotides corresponding to the first 17 amino acids (cyaBΔ1–17) or the MASE2 domain
(cyaBΔ1–216) were deleted. The mutant cyaB alleles encoding CyaBΔ1–17 and CyaBΔ1–216
were expressed from plasmids under the control of the IPTG-inducible tac promoter.
We assessed catalytic activity using a cAMP-dependent reporter gene (lacP1ΔlacI-lacZ)
based on the Escherichia coli lacP1 promoter, which was previously shown to reflect
intracellular cAMP levels in P. aeruginosa 30. Plasmid-borne cyaB alleles were transferred
to P. aeruginosa strain PAK lacking both chromosomally encoded adenylyl cyclases (cyaA
and cyaB) and harboring the lacP1ΔlacI-lacZ reporter in the vacant φCTX phage integration
site on the chromosome. We determined the induction conditions (IPTG concentration)
under which the plasmid-encoded CyaB proteins (wild-type and truncated forms) were
expressed at levels roughly equivalent to native CyaB in the wild-type strain as assessed by
immunoblotting bacterial lysates with anti-CyaB antibody generated against a synthetic
peptide corresponding to the extreme C-terminal portion of CyaB (Figure 1b). We then
assessed cAMP reporter activity under these conditions, correcting for minor differences in
protein levels based on quantitative analysis of CyaB immunoblots (Figure 1c). Wild-type
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CyaB, but not CyaBΔ1–17 or CyaBΔ1–216, restored wild-type reporter activity in
PAKcyaAB::lacP1ΔlacI-lacZ, with CyaBΔ1–216 displaying a more dramatic reduction in
reporter activity than CyaBΔ1–17. These results indicate that both the truncated proteins have
reduced activity relative to full-length CyaB. This finding, combined with the observation
that the CyaB catalytic domain has activity in vitro 12, suggests that the CyaB catalytic
domain retains function but that the N-terminal non-catalytic domain is required for full
activity in vivo. Overall, our results indicate that both the putative cytoplasmically exposed
N-terminal segment and the MASE2 domain influence CyaB AC activity in vivo.
Because CyaB is predicted to be an integral cytoplasmic membrane protein, we explored the
possibility that CyaBΔ1–17 and/or CyaBΔ1–216 are less active in vivo due to altered
subcellular localization. To determine the localization of CyaB, CyaBΔ1–17, and CyaBΔ1–216
within P. aeruginosa, we prepared fractions containing soluble (periplasmic and
cytoplasmic) and insoluble (total membrane) proteins from PAK expressing the
corresponding proteins. We then separated the total membrane fraction into inner and outer
membrane fractions by sarkosyl solubilization. An equivalent amount of each fraction was
analyzed by immunoblotting to detect CyaB, the cytoplasmic RNA polymerase (RNAP)
beta subunit 31, the inner membrane protein SecY, or the outer membrane protein OprF32.
Full-length CyaB and CyaBΔ1–17 were detected exclusively in the total membrane and inner
membrane fractions, whereas CyaBΔ1–216 was present only in the soluble cytoplasm-
periplasm fraction (Figure 2). These results demonstrate that CyaB is localized to the inner
membrane of P. aeruginosa and that localization is MASE2-dependent. In addition, the fact
that CyaB and CyaBΔ1–17 showed no difference in subcellular localization suggests that the
reduced activity of CyaBΔ1–17 is not due to improper targeting. Taken together, these results
reveal that both the extreme N-terminal segment and the putative MASE2 sensing domain
influence CyaB activity; the MASE2 domain functions in proper subcellular targeting, and
the N-terminal segment contributes in an as yet undefined way. It remains to be shown
whether these effect on CyaB activity are static or whether they contribute to physiological
CyaB regulation mechanisms.
Identification of CyaB residues involved in enzyme activation
We next sought to identify CyaB residues critical for catalytic activation. We conducted a
screen for CyaB mutants with elevated activity using the lacP1ΔlacI-lacZ reporter for cAMP
production. To enhance differences between the parent strain and mutants with elevated
CyaB activity, we performed the screen in a strain lacking PilG, a Chp chemosensing system
component that activates CyaB 12. Plasmid-based expression of wild-type levels of CyaB in
a cyaABpilG mutant does not complement reporter activity 12, leading to colonies that are
less blue on X-gal plates (data not shown). To identify cyaB mutations resulting in elevated
AC activity, we screened for suppressors of this pilG phenotype. We generated a library of
random substitution mutations in plasmid-borne cyaB (pMMBV2-cyaB) by PCR
mutagenesis and screened it in PAKcyaABpilG on X-gal plates under conditions that yielded
wild-type CyaB levels. To identify the cyaB lesions, we transferred the pMMBV2-cyaB
plasmids from darker colonies to E. coli DH5α, isolated plasmid DNA and sequenced cyaB.
We identified 28 cyaB clones harboring single missense mutations representing 10 unique
sites within CyaB (Table I): two in the linker region, six in the catalytic domain and two in
the C-terminal tail (Figure 3a). We then transferred a representative clone harboring each
unique mutation into PAKcyaAB to assess cAMP reporter activity. Due to saturation effects,
the lacP1ΔlacI-lacZ reporter does not accurately reflect cAMP concentrations above wild-
type level 12; 30. Therefore, we assayed the CyaB mutants in low salt media (5 mM versus
200 mM NaCl), a condition that results in reduced intracellular cAMP accumulation 33. To
determine the effect of salt concentration on reporter activity, we assayed PAK::lacP1ΔlacI-
lacZ in LB medium containing 5 mM or 200 mM NaCl and observed that reporter activity
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under high–salt medium is about 2.3-fold higher than in low-salt medium (Supplementary
Figure S1). We then assayed cAMP reporter activity of the CyaB mutants expressed in
PAKcyaAB::lacP1ΔlacI-lacZ under low-salt conditions. Although the strains were
expressed under identical induction conditions (50 μM IPTG), we examined CyaB levels by
quantitative immunoblot to address the possibility that the point mutations altered protein
stability. CyaB mutant protein levels were roughly comparable to that of wild-type CyaB
and to adjust for the subtle differences observed, we normalized reporter activity to CyaB
levels. The majority of CyaB mutants had significantly elevated cAMP reporter activity
(greater than fourfold) compared to that of wild-type CyaB expressed in the cyaAB mutant
(P ≤ 0.043) (Figure 3b). The activity of the R412H mutant was also elevated, but the
increase was not statistically significant. We also transferred a cyaB wild-type plasmid from
the cyaABpilG screening strain to PAKcyaAB, yielding equivalent activity to PAKcyaAB
expressing pMMBV2-cyaB. We thus conclude that the increased activity displayed by the
mutants is due to its nucleotide substitution in cyaB and the resulting change of a CyaB
protein residue, suggesting that enzyme activation is controlled by specific regions both
within and outside of the catalytic domain.
Crystal structure of the CyaB catalytic domain
In order to interpret data on the physiological (see above) and pharmacological (see below)
regulation of CyaB, we solved the crystal structure of the P. aeruginosa CyaB catalytic
domain. The enzymatically active CyaB catalytic core, comprised of residues 220–416
(CyaB220–416), was produced in E. coli and the homodimeric CyaB protein obtained from
purification was crystallized. The CyaB structure was then solved using Patterson search
techniques with the AC homodimer of CyaC from Spirulina platensis 16 as a search model,
and it was refined at 1.5 Å resolution to Rcryst and Rfree values of 18.6 % and 23.0 %,
respectively (Table II). The final CyaB model comprises residues 222–416 of two
monomers, A and B, in the asymmetric unit, with no residues in the disallowed region of the
Ramachandran plot and 99 % of the residues in the most favourable areas.
The overall structure of CyaB (Figure 4a,b) shows, besides small deviations in detail, the
general architecture of Class III AC enzymes 9; 17; 18. Each monomer contains a central
seven-stranded β-sheet, shielded from solvent by α-helices(Figure 4a ). The β-strands β1 to
β4 form a βαββαβ arrangement, and a two-stranded β sheet formed by β5 and extensions of
β4 protrude from the core of the domain. This small sheet interacts with β2 and β3 of the
partner monomer to form the wreath-like, catalytically active dimer (Figure 4b). Two active
sites are formed at the dimer interface, employing substrate binding and catalytic residues
from both monomers (Figure 4c).
CyaB more closely resembles the “closed” conformation of CyaC, which presumably
approximates a product complex, as opposed to the “open” conformation likely representing
the apo form before substrate binding (Figure 4d) 16. Thus, we expect the observed CyaB
conformation needs to open up to allow entry of the substrate, which would explain why no
substrate analog was visible in the active site after soaking experiments (data not shown).
Substrate analog cocrystallization attempts also resulted in apoenzyme crystals, which could
indicate that the observed, closed CyaB conformation crystallizes preferentially.
Comparison of the CyaB active site with the two CyaC conformations reveals that all
residues important for substrate binding and catalysis are in similar positions; however,
several showed substantial differences in their conformation. In particular, one of the two
conserved Asp residues responsible for binding the divalent metal ions, which in turn bind to
the substrate phosphates, is turned away from the ion positions (Asp234; Figure 4e). In
contrast to the active site entrance, this state appears like an open state, ready to
accommodate the metal ions, similar to one of two sites in the Class III GC Cya218. Similar
to Cya2, the catalytic dimer shows asymmetry, which might indicate that both active sites
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are in different states. This observation could even hint at half-of-the-sites activity, i.e. one
active site being in a catalytically active state is coupled to the second one being in an
inactive conformation, which was previously observed for other Class III cyclases 18; 34.
Structural implications for CyaB activation
The residues implicated in CyaB activation are highlighted in the crystal structure of the
CyaB catalytic domain in Figure 5a,b. The N- and C-terminal extensions of the CyaB core
crystallized here show similarities to corresponding regions in other AC enzymes, but they
have not been functionally or structurally characterized and were therefore omitted from our
analysis. It should be noted, however, that the activating mutations in C-terminus and linker
might indicate regulatory functions for these regions (although static effects cannot be
excluded – see above) and the MASE2 domain connected to the linker.
The most N-terminal activating mutation identified in the genetic screen (above),
Arg318Trp, affects a residue in the C-terminus of α3 on the surface of the catalytic core,
oriented toward the solvent (Figure 5a,b). Interestingly, the corresponding region of the
mammalian transmembrane ACs (tmACs) serves as a binding site for the regulatory
heterotrimeric G-protein subunit Gsα 15, and most likely Giα 35. Binding of G-protein
subunits is predicted to regulate tmAC activity by influencing the relative orientation of the
catalytic domains. The activating effect of changing Arg to a large, hydrophobic Trp might
indicate that within the full-length CyaB protein, this area is shielded from solvent and thus
also contributes to a regulatory interaction interface. However, the C-terminus of helix α3
and the connected loop show significant variations in length and sequence between the sAC-
like and tmAC families 9, and Arg318 is not conserved in other sAC-like ACs. Therefore,
Arg318 may mediate regulation by a CyaB-specific partner domain that is either part of full-
length CyaB (e.g., the MASE2 domain) or a separate regulatory protein. Interfering with this
regulatory interaction may be an attractive approach for drug development. It is tempting to
speculate that this protein region generally plays a role in adapting individual Class III ACs
to their specific regulators.
Several of the identified activating mutations affect positions involved in interactions with
two structural elements that undergo major conformational changes during the catalytic
cycle, the α1 helix and the β7/β8 loop 9. The mutations Leu326Pro (Figure 5a) and
Phe399Ile/His are also close to putative substrate binding residues (Arg329 and Lys397,
respectively) and could have direct effects on the local protein conformation, but their roles
in packing interactions seem more obvious explanations for the activating effects.
Leu326Pro affects the hydrophobic interface formed by the N-terminus of β4, the Arg318-
carrying α3 discussed above, and the flexible helix α1, which has to move toward the dimer
center 9; 36, either upon substrate binding 19 or substrate conversion 16. The mutation might
make α1 more flexible due to less tight packing, which would facilitate active site closure or
its induction through modulator binding. In contrast to Arg318Trp, which likely affects
CyaB activity only in presence of a partner domain or protein (see above), the Leu326Pro
mutation would be expected to directly increase specific activity of the isolated catalytic
domain. We therefore generated this single site variant, CyaB220–416-Leu326Pro, and
compared its specific activity to wildtype CyaB220–416. Consistent with the proposed
facilitating effect on the catalytic β7/β8 movement, the Leu326Pro mutation indeed
increased specific activity due to significantly faster substrate turnover, whereas the
substrate affinity was comparable to wildtype CyaB220–416 (Figure 5b). Similarly to Leu326,
residue Phe399, which was substituted with either His or Ile, resides in the β7/β8-loop that
moves, together with α1, during catalysis, thereby repositioning the phosphate-binding
residue Lys380. Exchange of the phenylalanine to a smaller (Ile) or less hydrophobic (His)
residue should weaken the packing of this loop against α4 and thereby make it easier for the
loop to move. The Glu377Gly mutation in α5 appears mainly solvent exposed in the closed
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conformation seen in the CyaB structure, but it might contribute to interactions to the β7/β8-
loop, similar to Phe399, in more open conformations. Although an increase in CyaB activity
due to the Arg412His mutation did not achieve statistical significance in our analysis, the
fact that this mutant was identified in our screen suggests this residue may still play a role in
enzyme activation. The mutation Arg412His affects a region opposite from the active site,
on the outside of the dimer and might thus influence interactions with regulatory partners
(domains or proteins), but its position at the base of the β7/β8 arm indicates that its effect
might again be based on influencing the movement of β7/β8. In contrast, the mutation
Ile352Thr affects a position not contacting β7/β8, but involved in packing β5 and α4 (Figure
4a,b; Figure 5a). This residue is located next to Thr351, which recognizes the substrate base
(Figure 4c) and likely needs to rearrange during transition state formation. We assume the
neighbouring residue influences these rearrangements through packing interactions that
modulate the backbone flexibility of this region.
While these hypothesized roles for the identified residues are consistent with our knowledge
on general mechanisms of Class III catalysis and regulation, they reveal mechanistic
differences from other Class III ACs, such as the one involving Arg318, suggesting that
interfering with these mechanisms should yield highly specific drugs.
CyaB belongs to the inorganic carbon-responsive family of sAC-like enzymes
Based on key active site polymorphisms, CyaB is assigned to the Class IIIb ACs, whose
members are characterized by responsiveness to CO2/HCO3− 9; 22. To examine the response
of CyaB217–463 to CO2/HCO3−, it was necessary to first determine its divalent metal ion
requirement and responsiveness to pH. CyaB217–463 activity was significantly higher in the
presence of Mn2+-ATP compared to Mg2+-ATP as substrate (Figure 6; note differences in
scale), as observed for most Class III ACs. In presence of either Mg2+-ATP or Mn2+-ATP,
CyaB217–463 activity increased with pH values ranging from 6.5 to 8.5 (Figure 6a). CO2/
HCO3− stimulated CyaB217–463 activity in the presence of either divalent, with optimal
stimulation occurring at pH 7.5 (Figure 6a). As Mn2+-ATP at pH 7.5 supported both optimal
specific activity and CO2/HCO3− dependent enzyme stimulation, further analysis was
performed under these conditions. Stimulation of specific enzyme activity was cation
independent (Figure 6b), and maximal stimulation occurred at 50 mM salt (Figure 6c). We
were unable to calculate an accurate EC50 because activity dropped precipitously at
concentrations >50 mM HCO3− presumably due to HCO3−-dependent precipitation of the
essential divalent cation. However, we were able to conclude that stimulation occurs over
physiologically relevant CO2/HCO3− concentrations (typically 5 to 25 mM). 20 mM CO2/
HCO3− increased enzyme activity compared to Cl− through an increase in enzyme turnover
(kcat of 3.8±0.2 min−1 and 1.2±0.1 min−1, respectively [S.E.M., N=6]) consistent with other
Class IIIb enzymes 22; 37. We thus conclude that physiological concentrations of CO2/
HCO3− modulate CyaB activity. It remains to be determined in which physiological
pathways this regulatory mechanism is employed.
Pharmacological inhibition of CyaB
CyaB might serve as target for novel antibiotics, and we therefore tested a number of known
Class III AC inhibitors for their efficacy against purified enzyme. Catechol derivatives of
estrogen (CE) were previously shown to be non-specific, noncompetitive inhibitors of Class
III ACs 38. Consistently, 2-hydroxy estradiol inhibited CyaB220–416 significantly at 100 μM
(Figure 7a). Previous crystallographic studies revealed that the catechol in CEs chelates the
catalytic divalent metal ion, and that the hydrophobic steroid scaffold binds to a pocket
present in all Class III cyclases, albeit with differences in the exact shape 38. An overlay of
CyaB with the CE complex of CyaC (Figure 7b) indeed shows the presence of an analogous
pocket in CyaB. Using the CyaC/CE structure, we developed more specific ligands, BCC2
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and BCC8, which specifically and potently inhibited CyaC and mammalian sAC, but not
tmACs 29. In CyaB, the CE binding pocket is slightly smaller, which might indicate that the
bulkier compound BCC2 should not be able to bind efficiently. Indeed, 100 μM BCC2 only
weakly inhibited CyaB activity (Figure 7a). This difference in BCC2 response among the
Class IIIb ACs examined indicates that exploiting the CE binding site may be an approach
enabling the development of specific inhibitors for individual ACs including CyaB.
All Class IIIb cyclases tested in our laboratories have been sensitive to the inhibitor KH7,
which appears to be specific for sAC-like ACs 27 and whose mechanism of action is
unknown. Surprisingly, the sAC-like enzyme CyaB was completely insensitive to KH7 at
concentrations up to 100 μM. Despite this observation, we hypothesized that minor
modifications of KH7 chemical space could yield effective inhibitors of CyaB. We therefore
screened 57 KH7-related compounds that differed with respect to the functional groups
attached to the KH7 acyl hydrazone backbone (Figure 7c,d). Several compounds increased
the assay signal, and we will test in a separate study whether they are indeed CyaB
activators, possibly employing the mechanism of the AC activator forskolin 9. However, one
of these compounds, KH7.148 (Figure 7d), inhibited CyaB activity with an IC50 of ~10 μM
(Figure 7e). Interestingly, KH7.148 was the only KH7-like compound with a catechol
moiety, and this shared chemical structure could indicate a mechanism of inhibition similar
to that of catechol estrogens 38. The steepness of the KH7.148 inhibition curve (Figure 7e)
could indicate cooperativeness compatible with binding to the CE site, which is partly
formed by the CE molecule bound to the second site of the AC dimer 38, but further
experimental work is required to clarify the KH7.148 mechanism. Interestingly, KH7.148 is
only a weak inhibitor of basal mammalian sAC activity, with an IC50 > 100 μM
(Supplementary Figure S2), showing that KH7.148 is not a promiscuous inhibitor but shows
selectivity even between these two closely related enzymes. These results indicate that it is
possible to develop highly specific inhibitors of CyaB, an important step in exploiting this
enzyme as a therapeutic target, and that KH7.148 can serve as a first lead compound.
Furthermore, the CyaB structure described here provides a starting point for future structure-
based drug development efforts.
DISCUSSION
The nucleotidyl cyclase Class III is a large family of proteins featuring a conserved catalytic
domain architecture but exhibits significant sequence variation in most residues not directly
involved in catalysis 9; 17. Consistently, the catalytic domains respond to different signalling
molecules, such as G-proteins, calmodulin, or CO2/HCO3−. Additionally, each Class III AC
catalytic domain is fused to unique regulatory domains 14, providing individual regulation
for specific ACs. The molecular basis for AC regulation has been characterized for a few
examples 39, and an emerging theme for AC regulation by different sensor domains and
binding proteins is an induced relative rotation of the catalytic domains that optimizes the
active site at the dimer interface 9; 15. Our finding that the MASE2 domain of P. aeruginosa
CyaB is required for membrane localization and full catalytic activity is consistent with a
model in which MASE2 receives an activating signal and, in response, influences the
relative rotation of the catalytic domains. Such a signaling function of MASE2 in CyaB is
supported by the fact that the MASE2 domain is distinct from the membrane anchors present
in other Class III ACs, but further experiments are needed to identify the factor(s) triggering
MASE2. Our assessment of the regulatory regions of CyaB beyond the MASE2 domain also
implicates the extreme N-terminal (cytosol-exposed) region of CyaB in catalytic regulation,
but it is not clear whether this regulation is direct, via contact with the catalytic domain
itself, or indirect, via inducing conformational alteration of MASE2 that in turn affects
catalytic activity.
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CyaB is required for production of multiple P. aeruginosa virulence factors including
secreted toxins and type IV pili (tfp), which are surface fibers at the bacterial pole mediating
adherence to host tissue and “twitching motility”, a surface-associated motility that involves
rapid cycles of pilus extension and retraction. CyaB is localized in the bacterial poles 40, a
location shared by the tfp biogenesis machinery 41 and components of the Chp
chemosensory system 40; 42. We predict that the MASE2 domain, which we show here is
required for inner membrane targeting, is also likely to be required for localization to the
bacterial poles. The localization pattern of CyaB, in combination with our finding that CyaB
catalytic activity is regulated by the Chp system 12, suggests the enzyme may be involved in
coupling an unknown signal to functional output (tfp extension and retraction), possibly as
part of a multi-protein complex anchored at the inner membrane. The Chp system complex
consists of a histidine kinase, accessory factors, and soluble receiver proteins anchored to an
inner membrane receptor (MCP). One intriguing possibility is that CyaB activity is
controlled via interaction with Chp system regulatory domains. In support of this model are
examples of Class III AC domains coupled to two-component kinase and receiver
domains 14; 43, and the report that AC/chemotaxis MCP chimeras produce cAMP in
response to the appropriate ligand 44; it remains to be shown, however, whether Chp system
regulation of CyaB is direct or indirect.
Although regulation by CO2/HCO3− is a common feature of sAC-like ACs, this regulation
has features specific for CyaB. For this AC, it is pH dependent with an optimum at 7.5 and
is distinct from previous modes of regulation which were either optimal at acidic pH, e.g.
Slr199137, or relatively pH independent, e.g. sAC 45. As mentioned, select fungi utilize CO2
to initiate a pathogenic response. An optimal pH of 7.5 for carbon regulation of CyaB might
represent a mechanism by which the relatively high CO2/HCO3− concentration in the
eukaryotic host can increase cAMP accumulation and contribute to the organism’s
pathogenic lifestyle.
The ACs of microbial sensor systems regulating virulence factors are interesting drug
targets. In two species of pathogenic fungi, Candida albicans and C. neoformans, a CO2-
sensing system based on a sAC-like AC and a carbonic anhydrase (CA) regulate virulent
growth 25; 26; 46; 47. Inhibition of CAs has been extensively studied, but despite some
promising novel approaches such as using novel chelating groups for the CA catalytic zinc
ion 48, it has proven difficult to develop compounds specific for the microbial enzyme but
inactive against host CAs 26. The fact that CyaB also responds to CO2/HCO3− might
indicate that a CA contributes to its regulation, but further studies will be needed to identify
this or other CyaB regulators and the mechanisms they employ. The only option currently
available to interfere with this P. aeruginosa system is direct inhibition of the CyaB catalytic
domain. Specific inhibition of Class III ACs is challenging, but progress in recent years has
stimulated efforts to exploit these proteins as drug targets 29; 49; 50. Intriguingly, we find that
the CyaB binding pocket for catechol estrogen and BCC2/829; 38 shows differences to those
in other sAC-like enzymes. Thus far, these differences correlated with compound sensitivity
suggesting that targeting this CyaB pocket is an attractive approach for developing specific
drugs. Also of interest, the compound KH7, which was effective against all previously tested
Class IIIb cyclases, is relatively inert towards CyaB. In contrast, a single catechol-containing
KH7-derived compound (KH7.148) proved to be a potent, selective inhibitor of CyaB,
indicating that this and other KH7 derivatives hold the potential to be developed into
therapeutic drugs that exploit CyaB’s role in virulence regulation. Mechanistic studies on
AC inhibition by KH7-like compounds will be an important part of the efforts to develop
AC-targeted therapeutics. Such efforts focused on P. aeruginosa should be complemented
by further studies on the CyaB regulatory mechanisms described here.
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Plasmid and strain construction
Strains used in this study are listed in Supplementary Table S1. The cyaB alleles encoding
truncated versions of CyaB (cyaBΔ1–17 and cyaBΔ1–216) for expression in P. aeruginosa
correspond to CyaB amino acid positions 18–463 or 217–463, respectively (cyaBΔ1–17
includes the existing methionine codon at position 18 whereas cyaBΔ1–216 has an added
methionine start codon). The expression plasmids pMMBV2-cyaBΔ1–17 and pMMB-
cyaBΔ1–216 were made by PCR amplification using chromosomal DNA from P. aeruginosa
strain PAK as template and either 5′ScyaB/3′PA3217 or 5′cyaB200/3′PA3217
oligonucleotide pairs, respectively (Supplementary Table S2). Amplified cyaBΔ1–17 and
cyaBΔ1–216 fragments were cloned into pDONR201 by Gateway cloning (Invitrogen) and
then transferred to pMMBV2GW or pMMBGW, respectively. All pMMB-derived plasmids
were transferred to PAKcyaAB::lacP1ΔlacI-lacZ by triparental mating as described 51.
cAMP reporter assay and immunoblotting
β-galactosidase assays were performed as previously described 12 using bacteria grown in
LB broth to mid-log growth phase (OD600 = 0.8). For the indicated assays, bacteria were
grown in LB with 5 mM NaCl (low salt) or 200 mM NaCl (high salt). For CyaB
immunoblot analysis, bacteria were normalized based on OD600 reading and pelleted by
centrifugation for 2 minutes at 13,000 x g. To create whole-cell lysates, bacteria were
suspended in 100 μl H20 and treated with 1 μl DNaseI (10 mg/ml) for 10 minutes at 37°C.
SDS/PAGE sample buffer (100 μl) was then added followed by incubation at 45°C for 45
minutes. Membranes were probed with affinity-purified antiserum against CyaB (1:5,000
dilution) and visualized by enhanced chemiluminescence as described 12. For quantitative
analysis of immunoblot autoradiographs, the signal intensity of bands corresponding to
CyaB, CyaBΔ1–17 or CyaBΔ1–216 was determined by densitometry using ImageJ software
(National Institutes of Health; rsbweb.nih.gov/ij/). To correct cAMP reporter activity values
for CyaB protein levels, the signal density of each sample relative to that of the control
(cyaA carrying empty vector or cyaAB carrying pMMBV2-cyaB) was determined and used
to calculate “relative activity” [relative activity = β-galactosidase activity (Miller units)/
[sample signal density/control signal density]]. Calculations to assess statistical significance
for relative activity values were made using an unpaired two-tailed t-test.
Bacterial fractionation
P. aeruginosa strains were grown in 500 ml LB broth with the indicated amount of
isopropyl-β-thiogalactoside (IPTG) at 37°C for 2.5 h and harvested by centrifugation at
10,000 x g. Fractionation was conducted based on the protocol of Boyd and Lory 52. Briefly,
the pellets were resuspended in 4 ml of 50 mM Tris, pH 7.5, 10 mM MgCl2 and treated with
RNase I and DNase I (50 μg/ml) for 10 min. Bacteria were lysed by 2 passages through a
French pressure cell (8000 lb/in2). Phenylmethysulfonyl fluoride (PMSF) was added to 100
μg/ml, lysozyme was added to 0.5 mg/ml, and the solution was incubated at room
temperature for 1 h. The lysate was centrifuged at 10,000 × g for 10 min to remove unlysed
cells and the resulting supernatant was centrifuged at 100,000 × g for 1 h to create total
membrane (pellet) and cytosol/periplasm (supernatant) fractions. The cytosol/periplasm
fraction was subjected to a second round of centrifugation at 100,000 × g for 1 h. The total
membrane fraction was suspended in 5 M urea, 100 mM Tris, pH 7.5 by passage through a
22-gauge needle to remove peripheral membrane proteins. The total membrane fraction was
centrifuged at 100,000 × g for 1 h and then subjected to a second wash with 5 M urea, 100
mM Tris, pH 7.5. The total membrane fraction was suspended in phosphate buffered saline
(PBS). Sarkosyl was added to 0.25 % and mixtures incubated on ice for 1 h and then
centrifuged at 100,000 x g for 1 h. The sarkosyl-soluble (inner membrane) fraction was
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subject to a second round of centrifugation at 100,000 × g. The sarkosyl-insoluble (outer
membrane) fraction was suspended in PBS plus 0.25 % sarkosyl and centrifuged again at
100,000 × g for 1 h. The final outer membrane fraction was suspended in PBS by passage
through a 22-gauge needle, centrifuged at 13,000 × g for 1 min to pellet debris and the
supernatant was transferred to a new tube. Protein concentrations for membrane and cytosol/
periplasm fractions were determined using BCA protein assay (Pierce). Samples for CyaB
immunoblotting were solubilised in SDS/PAGE sample buffer at 45°C for 45 minutes; all
other samples were solubilised at 95°C for 5 minutes. Samples were resolved by SDS/PAGE
on 12 % (CyaB) or 7.5 % (RNA polymerase (RNAP), OprF, and SecY) acrylamide gels and
transferred to nitrocellulose membranes. Immunoblots were probed with anti-CyaB antibody
(1:5,000) 12, antiserum specific for OprF (1:20,000) or SecY (1:5000) (32; gift of George
O’Toole), or antibody against E. coli RNAP β subunit (1:10,000; Neoclone). CyaB, OprF
and SecY were detected with horseradish peroxidase (HRP)-conjugated goat anti-rabbit Ig
(Jackson; 1:25,000); RNAP was detected with HRP-conjugated goat anti-mouse Ig (Jackson;
1:25,000). Immunoblots were developed using enhanced chemiluminescence reagents
(Millipore) and visualized by autoradiography.
CyaB mutagenesis and screening
PCR mutagenesis of cyaB was performed using Taq DNA polymerase (Qiagen), ATTB1start
and ATTB2stop oligonucleotides 7, 0.5 μM MgCl2 and pMMBV2-cyaB as template. The
pool of amplified products were cloned into pMMBV212 by Gateway cloning (Invitrogen)
and transformed into E. coli DH5α. The plasmid library carrying mutagenized cyaB was
transferred to PAKcyaABpilG::lacP1ΔlacI-lacZ by triparental mating. Dilutions of the
bacteria were plated on LB agar plates containing 25 μg/ml irgasan, 150 μg/ml carbenicillin
(carb), 40 μg/ml (X-gal) and 50 μg/ml IPTG. Colonies that appeared darker blue were
selected from plates containing approximately 500 colonies. Candidate plasmids were
recovered from P. aeruginosa by suspending the bacteria in water, incubating for 10 minutes
at 95°C followed by centrifugation for 1 min. An aliquot of the resulting supernatant was
transformed into E. coli DH5α, selecting on plates containing 30 μg/ml carb. pMMBV2-
cyaB mutant plasmids were harvested from E. coli DH5α for sequencing and then
transferred by triparental mating to PAKcyaAB::lacP1ΔlacI-lacZ.
The CyaB220–416 mutant Leu326Pro was generated from the CyaB220–416 wildtype
expression construct (see below) using the QuickChange Lightning kit (Agilent), and the
protein was expressed and purified as described for wildtype CyaB220–416(see below).
Recombinant protein production and purification
Open reading frames corresponding to the catalytic domain of CyaB from P. aeruginosa
strain PAK, with or without the C-terminal tail (residues 220–416 and 217–463 for
CyaB220–416 and CyaB217–463, respectively), were cloned into pQE30 (Qiagen), resulting in
an N-terminal His-tag with (CyaB220–416) or without (CyaB217–463) a TEV protease
cleavage site. Constructs were expressed in E. coli SG13009[pREP4] and M15[pREP4]
(Qiagen) in Luria-Bertani broth containing 100 μg/ml ampicillin and 50 μg/ml kanamycin
for 18 h at 20°C after induction with 0.5 mM IPTG at an OD600 of 0.6. Harvested cells were
resuspended in 50 mM Tris-HCl, pH 7, 200 mM NaCl, 3 mM DTT, 0.25 mM PMSF, treated
with 0.2 mg/ml lysozyme for 15 min on ice, and disrupted in a French Press. Cleared lysate
(50 min centrifugation at 50,000 x g and 4°C) was supplemented with 5 mM imidazole and
allowed to bind to Ni-NTA agarose (Qiagen) for 1 h at 4°C. The resin was washed with 10
volumes of 50 mM Tris-HCl, pH 7, 400 mM NaCl, 10 mM imidazole, 2 mM DTT, and
subsequently with 10 volumes of 50 mM Tris-HCl, pH 7, 200 mM NaCl, 15 mM imidazole,
2 mM DTT, and protein eluted with TEV protease overnight at 4°C (CyaB220–416) or 10
volumes of 50 mM Tris-HCl, pH 7, 200 mM NaCl, 150 mM imidazole, 2 mM DTT
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(CyaB217–463). Cleaved CyaB220–416 protein was eluted in 50 mM Tris-HCl, pH 7, 150 mM
NaCl, 2 mM DTT and concentrated in a 10 kDa Amicon concentrator (Millipore). For
crystallography, CyaB220–416 was subjected to size-exclusion chromatography in 20 mM
Tris-HCl, pH 7, 100 mM NaCl, 2 mM DTT on a Superose-12 column. Pure fractions were
pooled, concentrated, frozen in aliquots in liquid nitrogen, and stored at 80°C. Slr1991
residues 120–337 were expressed and purified as previously described 37.
Activity assays
Regular AC assays were done in a 30 μl volume of 20 mM Tris-HCl, pH 7, 100 mM NaCl, 5
mM ATP, 10 mM MgCl2, and 0.5–2.25 μg purified CyaB protein. Samples were incubated
at 30°C for 30 min, and cAMP concentrations determined by using an ELISA (Biomol)
according to the manufacturers’ instructions. Experiments were done in duplicates and
results shown are representatives of at least three repetitions. AC assays to assess the
response to CO2/HCO3− were performed as previously described 45. Deviations from this
setup are noted in the description of the respective results.
Crystallization, data collection and structure solution
For crystallization of CyaB220–416, drops were mixed from 0.8 μl protein (10 mg/ml) and 0.8
μl reservoir (0.1 M MES, pH 6.5 and 12 % w/v PEG 20,000), equilibrated against 0.4 ml
reservoir at 20°C. Crystals were transferred to cryo-protection solution containing reservoir
components plus 25 % glycerol. A complete diffraction data set of a CyaB220–416 crystal
of space group P2 was collected at 100 K at Swiss Light Source beamline X10SA. Indexing,
scaling, and merging were done with XDS 53. The structure of CyaB220–416 was solved by
using Patterson search techniques with PHASER 54, using the AC CyaC homodimer 38
(PDB ID 1WC1) as search model. For completing the model, manual model building in
Coot 55 was alternated with positional and individual B-factor refinement with REFMAC 56.
Close to convergence of the refinement, solvent atoms and a glycerol molecule were
included. The refined structure was analyzed by using Coot and ProCheck 57, and structural
figures were generated with PyMOL (www.pymol.org) if not stated otherwise.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Characterization of CyaB, an adenylyl cyclase regulating P. aeruginosa
virulence
• The MASE2 domain of CyaB acts as membrane anchor and influences cyclase
activity
• Residues involved in CyaB regulation identified using a random mutagenesis
screen
• A CyaB catalytic core crystal structure reveals location and function of the
residues
• Modulation of CyaB through CO2/HCO3− and known AC inhibitors
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Figure 1. Regions outside the CyaB catalytic domain affect activity in vivo
(a) Diagram of the domain organization of native CyaB and the truncated CyaB proteins
CyaBΔ1–17 and CyaBΔ1–216. The N-terminal MASE2 domain (PF05230) contains six
predicted transmembrane α-helices (not shown); the C-terminus contains a guanylate_cyc
(PF00211) domain present in Class III GCs and ACs. Relevant amino acid positions are
indicated. (b) Immunoblot of whole-cell lysates from cyaA or cyaAB mutants carrying either
an empty vector (V), pMMBV2 expressing cyaB or cyaBΔ1–17, or pMMB expressing
cyaBΔ1–216, probed with anti-CyaB antibody. Expression of cyaB or cyaBΔ1–17 from
pMMBV2 at 50 or 20 μM IPTG, respectively, yielded a level of CyaB approximately
equivalent to that of the wild-type strain; expression of cyaBΔ1–216 from the pMMB
plasmid, which has higher tac promoter activity, required 10 μM IPTG. Samples were
normalized based on bacterial number. Molecular weight size standards are indicated. (c)
cAMP reporter activity (corrected for CyaB protein levels) in the cyaA or cyaAB mutants
carrying either an empty vector (V), pMMBV2 expressing cyaB or cyaBΔ1–17, or pMMB
expressing cyaBΔ1–216. All strains contained the chromosomal lacP1ΔlacI-lacZ reporter and
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were grown to mid-exponential growth phase with amount of IPTG indicated above.
Equivalent samples were assayed for β-galactosidase activity and analyzed by quantitative
immunoblot. CyaB levels were normalized based on the cyaA mutant carrying V and used to
calculate relative activity. Bars represent the mean ± SEM of at least three independent
experiments. The asterisk (*) indicates that the values for the indicated strains were
significantly different (P < 0.0001) when compared pairwise to the value for the cyaA
mutant carrying V.
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Figure 2. The MASE2 domain is required for CyaB membrane localization
Bacterial cell fractions from PAKcyaAB expressing wild-type CyaB or CyaBΔ1–17 from
pMMBV2, or CyaBΔ1–216 from pMMB. Strains were grown to mid-exponential growth
phase with 50 (CyaB), 20 (CyaBΔ1–17) or 10 (CyaBΔ1–216) μM IPTG. Whole-cell lysates,
soluble (cytoplasmic-periplasmic) fractions and membrane (total, inner, and outer) fractions
were subjected to SDS-PAGE and probed with antibody specific for CyaB, SecY, OprF or
RNAP β subunit. For CyaB immunoblots, 15 μl of whole-cell lysate or 15 μg of fractionated
protein was loaded; for all other immunoblots, 2μl of whole-cell lysate or 2 μg of
fractionated protein was loaded. RNAP β subunit (~150 kDa) served as a control for
cytoplasmic localization; SecY (~50 kDa) and OprF (~34 kDa) served as inner and outer
membrane fraction markers, respectively. Molecular weight size standards are indicated.
Samples were fractionated at the same time, but were immunoblotted on different days. The
immunoblots are representative of at least two independent experiments.
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Figure 3. Analysis of CyaB mutants with increased enzyme activity
(a) Diagram indicating the site of CyaB missense mutations obtained in the screen for
elevated cAMP-dependent reporter activity. (b) cAMP reporter activity (corrected for CyaB
protein levels) in the cyaAB mutant carrying pMMBV2 expressing either cyaB, a cyaB wild-
type clone from the screening strain (cyaB*), or the indicated cyaB mutant. All strains
contained the chromosomal lacP1ΔlacI-lacZ reporter. Strains were grown to mid-
exponential growth phase in LB with 5 mM NaCl (low salt) and 50 μM IPTG. Equivalent
samples were assayed for β-galactosidase activity and analyzed by quantitative immunoblot.
CyaB levels were normalized based on the cyaAB mutant carrying pMMBV2-cyaB and used
to calculate relative activity. Bars represent the mean ± SEM of three independent
experiments. Values for all CyaB mutants (except R412H)) were significantly different (P ≤
0.043) when compared pairwise to the value for the cyaAB mutant carrying pMMBV2-cyaB.
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Figure 4. Crystal structure of the CyaB catalytic domain
(a) Overall structure of the CyaB monomer with labelled secondary structure elements. The
connectivity is indicated through rainbow coloring from blue (N-terminus) to red (C-
terminus). (b) Overall structure of the catalytic CyaB homodimer, with chain A and B
colored orange and light orange, respectively. The locations of the two active sites at the
dimer interface, derived through comparison to other Class III ACs, are indicated. (c) Active
site of CyaB, with ATPαS and the two divalent ions A and B modelled into the substrate
binding pocket through overlay with a CyaC/ATPαS complex (PDB ID 1WC1). Conserved
Class IIIb catalytic residues are shown as sticks and labelled (* indicates residues from
monomer B). (d) Comparison of CyaB (light orange) with the open (light grey; PDB ID
1WC0) and closed (dark grey; 1WC1) conformations of CyaC. The structural elements
showing major movements during catalysis are highlighted (CyaB: dark orange; CyaC open:
green; CyaC closed: red) and labelled. (e) Close view of the empty CyaB (grey) active site
overlaid with the CyaC/ATPαS complex (green; PDB ID 1WC1). The magnesium ions from
the CyaC structure are shown as yellow spheres, and the Asp of CyaB are labelled and
colored according to atom type. The Asp side chains of CyaB are partially and fully rotated,
respectively, opening up the ion binding sites. In CyaC, in contrast, the Asp side chains are
oriented toward the ions and coordinate each magnesium with one oxygen atom.
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Figure 5. Structural analysis of residues involved in CyaB regulation
(a) Activating mutations identified in a genetic screen are shown as sticks in the front and
top views of the CyaB crystal structure, and (b) as blue patches on the surface of the
structure. Amino acids at these positions and the substituting amino acid are indicated with
one-letter codes. (c) Comparison of specific activities of CyaB220–416 wildtype (●) and the
CyaB220–416-Leu326Pro mutant (■) determined at 10 mM Mn2+ and increasing ATP
concentrations.
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Figure 6. Regulation of CyaB by bicarbonate
(a) 0.17 μM (Mn2+-ATP) or 13.7 μM (Mg2+-ATP) CyaB217–463 was assayed at varying pH
at 40°C with 0.2 mM (Mn2+-ATP) or 1 mM (Mg2+-ATP) substrate in the presence of 20
mM NaCl (□) or NaHCO3− (Δ). (b) 0.17 μM CyaB217–463 was assayed at pH 7.5, with 30
mM salt at 40°C and 0.2 mM Mn2+-ATP as substrate. (c) 0.17 μM CyaB217–463 was assayed
at pH 7.5 and 40°C with varying concentrations of NaHCO3 and NaCl to maintain a
constant 180 mM total salt concentration, and 0.2 mM Mn2+-ATP as substrate. The drop of
activity beyond 50 mM NaHCO3 is likely a precipitation artefact typically observed for
Mn2+at high NaHCO3 concentrations.
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Figure 7. Regulation of CyaB by small molecule drugs
(a) Inhibition of CyaB AC activity by 100 μM 2-CE, BCC2, and BCC8, respectively. (b)
Comparison of the CE binding sites of CyaC (A) and CyaB (B). The inhibitor was put into
the corresponding CyaB site based on an overlay with the crystal structure of the CyaC/CE
complex (PDB ID 2BW7). (c) Screening for CyaB inhibitors by testing a library of KH7
derivatives. AC assays were performed with 1 mM ATP in the presence of 10 μM (blue
bars) or 100 μM (red bars) drug. (d) Chemical structures of KH7 and KH7.148. (e) Dose-
response curve for inhibition of CyaB by KH7.148, indicating an IC50 of ~10 μM.
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Table I
CyaB mutants with altered cAMP reporter activity.
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Table II
Crystallographic data and refinement statistics
CyaB
Space group P2
Unit cell constants a = 51.4 Å, b = 36.3 Å, c = 94.8 Å; β = 98.76°
Resolution limit 1.5 Å
Unique reflections 50946
<I / σ>(a) 20.6 (4.6)
Completeness(a) 91.2 % (61.4 %)
Rmerge(a) 5.4 % (36.4 %)
Refinement resolution 47.8 – 1.5 Å
Total reflections used 48397
Rcryst / Rfree(b) 18.6 % / 23.0 %
Atoms: protein / solvent + glycerol 3054 / 323
R.m.s.d. bond lengths 0.028 Å
R.m.s.d. Bond angles 2.4°
Average B-factor: protein / solvent + glycerol 20.8 Å2 / 32.1 Å2
(a)
 Numbers in parentheses are for the outermost shell (1.5–1.6 Å)
(b)
Rfree was calculated from 5 % of measured reflections omitted from refinement.
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